Expression of GLUT-2 Antisense RNA in β Cells of Transgenic Mice Leads to Diabetes*

(Received for publication, May 12, 1994, and in revised form, September 9, 1994)

Alfonso Valera†, Gemma Solanes‡§, Josefina Fernández-Alvarés§, Anna Pujols§, Jorge Ferrer§, Guillermina Asensi, Ramon Gomis§, and Fatima Bosch§¶

From the 2Department of Biochemistry and Molecular Biology, School of Veterinary Medicine, Autonomous University of Barcelona, 08193 Bellaterra and the 1Department of Endocrinology, Hospital Clinic, University of Barcelona, 08026 Barcelona, Spain

An insulin response to glucose is required to correct hyperglycemia. Two proteins, the glucose transporter GLUT-2 and the glucose-phosphorylating enzyme glucokinase, have been implicated in the control of glucose metabolism in β cells. To study the role of glucose transporter GLUT-2 in the regulation of insulin secretion and in the development of diabetes mellitus, we have obtained transgenic mice expressing high levels of GLUT-2 antisense RNA in β cells. Western blot analysis showed an 80% reduction in GLUT-2 protein in the β cells of these animals. Islets from transgenic mice showed impaired glucose-stimulated insulin secretion. In addition, much higher levels of blood glucose were detected in transgenic mice than in controls when glucose tolerance tests were performed. These results suggest that the reduction of GLUT-2 in the pancreas could be a crucial step in the development of diabetes mellitus.

Glucose homeostasis is maintained within a normal range by the adjustment of glucose production in the liver and glucose uptake by peripheral tissues, mainly skeletal muscle (1). The β cell regulates this balance by secreting insulin so that normoglycemia is established. The main characteristics of non-insulin-dependent diabetes mellitus (NIDDM) are increased glucose production by the liver, together with a lack of glucose uptake by peripheral tissues and a decrease in glucose-stimulated insulin secretion by the pancreatic β cells (1, 2). Although NIDDM is a widespread metabolic disease, its pathogenesis is unknown. Glucose transport and metabolism in the β cell are necessary for both prestormed insulin release and insulin synthesis de novo (3). High $K_{g}$ glucose uptake in β cells is originated by glucose transporter GLUT-2 (4). Several reports have indicated that a decrease in GLUT-2 is noted in various animal models of diabetes, which suggests that GLUT-2 is required for normal glucose sensing (5–9). Furthermore, transfection of AtT-20ins cells with the GLUT-2 cDNA confers glucose-stimulated insulin secretion and glucose regulation of insulin biosynthesis (10), and this could not be reproduced after GLUT-1 transfection (11). The glucose-phosphorylating enzyme glucokinase has also been considered to be a crucial step in the control of glucose metabolism in pancreatic β cells (3, 12). Both GLUT-2 and glucokinase have high $K_{g}$ for glucose, which ensures that the uptake of glucose is proportional to the highest physiological extracellular glucose concentration. It has been suggested that GLUT-2 and glucokinase might work in concert as a “glucose sensing apparatus” that modulates insulin secretion in response to changes in circulating glucose concentrations (1, 13).

The present study was undertaken to investigate the role of a chronic decrease of GLUT-2 in pancreatic β cells in relationship to glucose-induced insulin secretion, using transgenic animals. To decrease functional GLUT-2 glucose transporter in the islets, we have designed a chimeric gene that expresses a GLUT-2 antisense RNA specifically in β cells. Transgenic mice expressing a GLUT-2 antisense RNA showed a high reduction in GLUT-2 protein in β cells, which led to impaired glucose-stimulated insulin secretion, hyperglycemia, and altered glucose tolerance tests.

EXPERIMENTAL PROCEDURES

Generation of Transgenic Mice—The general procedures used for microinjection of the RIP-Vanti-GLUT-2 chimeric gene were described (14). Fertilized mouse eggs were flushed from the oviducts of superovulated C57BL6SJL mice 6–8 h after ovulation. Male pronuclei of the fertilized eggs were injected with 2 pl of DNA solution (approximately 2 ng/μl), and viable embryos were reimplanted in the oviducts of pseudopregnant mice. The animals were tested for the presence of the transgene by Southern blot of DNA tail samples taken at 3 weeks of age.

Treatment of Animals—Mice were fed ad libitum with a standard diet (Panlab, Barcelona, Spain) and kept under a light-dark cycle of 12 h (lights on at 8:00 a.m.). When stated, mice were a fed high carbohydrate diet and water ad libitum for 1 week. The high carbohydrate diet was purchased from Nutritional Biochemical Corp., Cleveland, Ohio. This synthetic diet contained 80.5% sucrose, 10.2% casein, 0.3% t-methionine, 4% cottonseed oil, 2% brewer’s yeast, and 2% mineral mix plus 1% vitamin mix.

Blood samples were obtained between 9 and 10 a.m. by decapitation of mice fed a standard or a high carbohydrate diet. Determination of insulin levels in serum samples were made by RIA (CIS, Biointernational, Gif-Sur-Yvette, France). Serum glucose concentration was measured enzymatically (Glucquant®, Boehringer Mannheim, Germany). The intraperitoneal glucose tolerance test was performed between 10 and 11 a.m. in fed control and transgenic mice. After anesthetizing the mice with avertin, a blood sample was obtained from the tail vein to measure the basal level of glucose by using a Reflotron® autoanalyzer (Boehringer Mannheim). Mice were subsequently administered an intraperitoneal injection of 1 mg of glucose/g of body weight. Blood samples (30 μl) were obtained at different times from the same animals and the levels of glucose determined.

RNA Analysis—Total RNA was obtained from pancreas by the guanidine isothiocyanate method (15). RNA samples (30 μg) were electrophoresed on 1% agarose gel containing 2.2 μ formaldehyde. Northern blots were hybridized with an EcoRI GLUT-2 riboprobe. A 600-bp BstXI fragment of the GLUT-2 cDNA was inserted into a pBluescript vector, linearized with EcoRV, and transcribed in vitro from the T7 promoter, using T7 RNA polymerase. This generated a 650-nucleotide run-off that was used as riboprobe to detect the GLUT-2 antisense RNA from the transgene.

GLUT2 Protein Analysis—Western blot analysis was performed by standard procedure (16) from total cellular lysates of islets. Islets were

* This work was supported in part by Grants 92/0791 and 94/0795 from the Fondo Investigaciones Sanitarias de la Seguridad Social and Grant Sal 91/635 from the Comisión Interministerial de Ciencia y Tecnología, Spain. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

† Recipient of a predoctoral fellowship from Direccio General Universitats, Generalitat de Catalunya.

‡ To whom all correspondence should be addressed. Tel.: 34-3-5811043, Fax: 34-3-5812006.

§ The abbreviations used are: NIDDM, non-insulin-dependent diabetes mellitus; RIA, radioimmunoassay; bp, base pairs.

28543
expression of GLUT-2 Antisense RNA in \( \beta \) cells.

**Fig. 1.** Schematic representation of the RIP-I/anti-GLUT-2 chimeric gene used to create transgenic animals. The SacI/BamHI fragment (−570 bp to +3 bp) of the rat insulin promoter (21) was linked to a BamHI/XhoI fragment of the rabbit \( \beta \)-globin gene, which included the two last exons, the last intron, and the 3' region linked to the SV40 enhancer. The \( \beta \)-globin fragment and SV40 enhancer were included in order to ensure expression of the antisense transgene. An EcoRI fragment (+105 bp to +1594 bp) of the GLUT-2 cDNA (19) was introduced in reverse orientation at the EcoRI site of the second exon of the \( \beta \)-globin gene. The 4.26-kilobase pair SacI-XhoI fragment containing the entire chimeric gene was used to obtain transgenic mice. The triangle (\( \triangledown \)) represents the polyadenylation signal from the \( \beta \)-globin gene.

---

**RESULTS AND DISCUSSION**

To decrease functional GLUT-2 glucose transporter in the islets, we have designed a chimeric gene that expresses a GLUT-2 antisense RNA. It was obtained by linking the rat insulin I promoter (RIP-I) (−570 bp to +3 bp) to an inverted fragment (−105 bp to +1594 bp) of the rat GLUT-2 cDNA (19) (Fig. 1). The fragment of rat GLUT-2 cDNA used in this study shares 94% homology with the mouse cDNA (20). The RIP-I promoter directs the expression of chimeric genes specifically in pancreatic \( \beta \) cells (21). Five trans-mitter-transgenic founder mice were obtained when the RIP-I/anti-GLUT-2 chimeric gene was microinjected into fertilized eggs. These transgenic animals carried from 5 to 25 intact copies of the transgene (data not shown). In the experiments described below we used F1 and F2 mice (2–4 months old) from the IG-1 line, which contained a larger number of copies of the transgene (data not shown). In the experiments described below we used F1 and F2 mice (2–4 months old) from the IG-1 line, which contained a larger number of copies of the transgene (data not shown).

Insulin gene expression is induced by glucose (1, 2). Control and transgenic mice were fed a high carbohydrate diet for 1 week to induce the expression of the transgene. Total RNA was obtained from the pancreas and analyzed by Northern blot. High levels of GLUT-2 antisense RNA were detected in the pancreas of transgenic mice fed either a standard or a high carbohydrate diet because of the high expression from the insulin promoter (Fig. 2A). No expression of the transgene was detected in other tissues examined, like liver and kidney (data not shown).

**Fig. 2.** Expression of GLUT-2 antisense RNA in pancreatic \( \beta \) cells. A, analysis by Northern blot of GLUT-2 antisense RNA levels. Total RNA was extracted and analyzed as indicated under "Experimental Procedures" from the pancreas of control (lanes 3–6) and transgenic (lanes 1 and 2) mice fed a standard (lanes 1–4) or a high carbohydrate (lanes 5–8) diet. B, content of GLUT-2 protein in isolated islets. Western blot analysis was performed by standard procedures from total cellular lysates of islets, as indicated under "Experimental Procedures." To detect GLUT-2 a rabbit antiseraum to GLUT-2, diluted at 1:600, was used. The appearance of GLUT-2 as a doublet resulted from partial proteolytic degradation of the transporter during the islet isolation procedure before cell lysis. Lane 1, control; lane 2, transgenic mice.
Serum concentrations of glucose and insulin in fed mice

Serum determinations were made periodically from blood obtained in the morning (9-10 a.m.). Insulin levels were measured by RIA. Glucose was determined enzymatically as indicated under "Experimental Procedures." Results are mean ± S.E. of the animals indicated in parentheses.

| Glucose | Insulin |
|---------|---------|
| mg/dL   | ng/ml   |
| Control | 180 ± 20 (n = 20) | 1.71 ± 0.20 (n = 15) |
| Transgenic | 329 ± 28 (n = 20) | 1.17 ± 0.18 (n = 18) |

**REFERENCES**

1. Taylor R., and Aguina, L. (1988) Biochem. J. 250, 625-649
2. McGarry, J. J. (1992) Science 258, 766-770
3. Meglasson, M. D., and Matuschek, M. F. (1986) Diabetes Metab. Rev. 3, 163-214
4. Unger, R. H. (1981) Science 210, 120-124
5. Chen, L., Alam, T., Johnson, J. H., Hughes, S., Newgard, C. B., and Unger, R. H. (1991) Proc. Natl. Acad. Sci. U.S.A. 87, 4088-4092
6. Thorens, B., Weir, G. C., Lebey, J. L., Lechti, H. F., and Bonner-Weir, S. (1990) Proc. Nat. Acad. Sci. U.S.A. 87, 6485-6489
7. Johnson, H. F., Ongawa, A., Chen, L., Orci, L., Newgard, C. B., Alam, T., and Unger, R. H. (1990) Science 250, 546-549
8. Orci, L., Ravazzola, M., Bostedt, D., Iman, L., Amherdt, M., Peterson, G., Newgard, C. B., Johnson, J. H., and Unger, R. H. (1990) Proc. Natl. Acad. Sci. U.S.A. 87, 3050-3054
9. Orsi, L., Ravazzola, M., Bostedt, D., Iman, L., Amherdt, M., Peterson, G., Newgard, C. B., Johnson, J. H., and Unger, R. H. (1990) Proc. Natl. Acad. Sci. U.S.A. 87, 3050-3054
10. Hughes, S. D., Johnson, J. H., Quinn, C., and Newgard, C. B. (1992) Proc. Natl. Acad. Sci. U.S.A. 87, 3050-3054

**FIG. 3. Intraperitoneal glucose tolerance test.** Fed transgenic mice had higher basal blood glucose levels than control. These mice were given an intraperitoneal injection of 1 mg of glucose/g of body weight. Blood samples were taken at the times indicated from the tail vein of the same animals as indicated under "Experimental Procedures." Glucose was determined in 30 μl of blood with a Reflotron® (Boehringer Mannheim). Results are mean ± S.E. of 8 transgenic and 6 control mice.

**FIG. 4. Glucose-induced insulin secretion by isolated islets.** Insulin secretion at 0, 2, 5, 10, and 15 min was determined, as indicated under "Experimental Procedures," in islets isolated from control and transgenic mice. Results are the mean ± S.E. of 25 animals in each group.

centrations close to the $K_m$ of GLUT-2 (11.1 and 16.7 mM) (4), an impairment in glucose-stimulated insulin secretion was detected. In contrast, when amino acid-stimulated insulin secretion was studied no decrease was detected in islets from transgenic mice compared to controls. Isolated islets were cultured in 10 mM glucose plus 10 mM glutamine for 90 min, and the insulin levels noted in the incubation medium were: 83.48 ± 1.17 μg/ml (n = 15) in islets from control mice (6, 12) in dexamethasone-induced diabetes. Such a model allows for the study of the effect of decreased GLUT-2 expression in the absence of diabetic hyperglycemia.

**Expression of GLUT-2 Antisense RNA in β Cells**

Type II diabetes (23), a marked reduction in GLUT-2 expression is observed. Thus, every rodent model of NIDDM shows a defect in glucose-stimulated insulin secretion, together with a reduction in the insulin secretory activity of the islets of these transgenic mice. The reduction of GLUT-2 may lead to secondary acquired abnormalities in the β cells. A recent study by Hughes et al. (11) shows that the role of GLUT-2 in glucose-stimulated insulin release may not be related to the rate of glucose flux and metabolism, but rather might require physical coupling of the transporter with other proteins involved in glucose signaling.

In agreement with our results, which suggest that a primary decrease in functional GLUT-2 levels may lead to diabetes, it has very recently been reported that a mutation in the GLUT-2 gene of a diabetic patient, which results from a single amino acid change (valine 197 to isoleucine) abolished transport activity when the mutant protein was expressed in Xenopus oocytes (24). Since the patient only had about 50% of the GLUT-2 protein of a non-diabetic individual, this reduction in GLUT-2 protein might have reduced glucose-stimulated insulin release and thus contributed to the development of diabetes in this patient.

Finally, transgenic mice expressing the RIP/anti-GLUT-2 chimeric gene provide an experimental model in vivo for addressing questions related to β cell function in the absence of the normal expression of GLUT-2.

**Acknowledgments**—We thank G. I. Bell, University of Chicago, for GLUT-2 cDNA; B. Thorens, University of Lausanne, for mouse GLUT-2 antisense; R. Casamatta for RIA insulin determinations; W. Malaisse, J. Girard, and R. Rycroft for critical review of the manuscript; and C. H. Ros for excellent technical assistance.

**REFERENCES**

1. Taylor R., and Aguina, L. (1988) Biochem. J. 250, 625-649
2. McGarry, J. J. (1992) Science 258, 766-770
3. Meglasson, M. D., and Matuschek, M. F. (1986) Diabetes Metab. Rev. 3, 163-214
4. Unger, R. H. (1991) Science 251, 1200-1204
5. Chen, L., Alam, T., Johnson, J. H., Hughes, S., Newgard, C. B., and Unger, R. H. (1990) Proc. Natl. Acad. Sci. U.S.A. 87, 4088-4092
6. Thorens, B., Weir, G. C., Lebey, J. L., Lechti, H. F., and Bonner-Weir, S. (1990) Proc. Nat. Acad. Sci. U.S.A. 87, 6485-6489
7. Johnson, H. F., Ongawa, A., Chen, L., Orci, L., Newgard, C. B., Alam, T., and Unger, R. H. (1990) Science 250, 546-549
8. Orci, L., Ravazzola, M., Bostedt, D., Iman, L., Amherdt, M., Peterson, G., Newgard, C. B., Johnson, J. H., and Unger, R. H. (1990) Proc. Natl. Acad. Sci. U.S.A. 87, 3050-3054
9. Orsi, L., Ravazzola, M., Bostedt, D., Iman, L., Amherdt, M., Peterson, G. C., Newgard, C. B., Johnson, J. H., and Unger, R. H. (1990) Proc. Natl. Acad. Sci. U.S.A. 87, 3050-3054
10. Hughes, S. D., Johnson, J. H., Quinn, C., and Newgard, C. B. (1992) Proc. Natl. Acad. Sci. U.S.A. 89, 7953-7957
Expression of GLUT-2 Antisense RNA in β Cells

11. Hughes, S. D., Quaade, C., Johnson, J. H., Ferber, S., and Newgard, C. B. (1993) J. Biol. Chem. 268, 15205-15212
12. Liang, Y., Najafi, H., and Matschinsky, F. M. (1990) J. Biol. Chem. 265, 18866-18866
13. Newgard, C. B., Quaade, C., Hughes, S. D., and Millburn, J. L. (1990) Biochem. Soc. Trans. 18, 851-853
14. Hogan, B., Costantini, F., and Lacy, E. (1986) Manipulating the Mouse Embryo: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
15. Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J., and Rutter, W. J. (1979) Biochemistry 18, 5294-5299
16. Winston, S. E., and Fuller, S. A. (1991) in Current Protocols in Immunology (Coligan, J. E., Kruisbeek, A. M., Margulies, D. H., Shevach, E. M., and Strober, W., eds) pp. 8.10.1-8.10.5, John Wiley & Sons, New York
17. Lacy, P. E., and Kostianovsky, M. (1987) Diabetes 36, 35-39
18. Sokal, R. R., and Rohlf, F. J. (1989) Biometry: The Principles and Practice of Statistics in Biological Research, W. H. Freeman, San Francisco
19. Thorens, B., Stark, H. K., Kaback, H. R., and Lodish, H. F. (1990) Cell 65, 281-290
20. Suzue, K., Lodish, H. F., and Thorens, B. (1990) Nucleic Acids Res. 17, 10099-10113
21. Dandoy-Dron, F., Monthioux, E., Jami, J., and Bucchini, D. (1991) Nucleic Acids Res. 19, 4925-4930
22. Thorens, B., Wu, Y.-J., Leaky, J. L., and Weir, G. C. (1992) J. Clin. Invest. 90, 77-85
23. Ogawa, A., Johnson, J. H., Ohneda, M., McAllister, C. T., Inman, L., Alam, T., and Unger, R. H. (1992) J. Clin. Invest. 90, 497-504
24. Mueckler, M., Kruse, M., Strube, M., Riggs, A. C., Chiu, R. C., and Permutt, M. A. (1994) J. Biol. Chem. 269, 17765-17767